News Release

Theratechnologies Announces Financial Results and Highlights For the Second Quarter 2008

- Disclosure of positive results for the confirmatory Phase 3 trial
- Update on the strategic review
- Agreement signed with the Massachusetts General Hospital and Dr. Grinspoon
- License agreement signed with PDC Biotech GmbH

Montréal, Canada – July 9, 2008 – Theratechnologies (TSX:TH) today announced its financial results for the second quarter ended May 31, 2008 and reviewed recent corporate highlights.

"I am proud with the clinical results that we announced a few weeks ago. Theratechnologies is one of the rare Canadian biotechnology companies to have obtained positive results in a confirmatory Phase 3 trial, a critical step that paves the way for the submission of a New Drug Application for the tesamorelin clinical program," commented Mr. Yves Rosconi, President and CEO.

"With $72 million available, Theratechnologies has a solid balance sheet, which allows for the development of the tesamorelin clinical program," noted Mr. Luc Tanguay, Senior Executive Vice President and CFO.

Recent Highlights

Disclosure of positive results for the confirmatory Phase 3 trial

On June 18, 2008**,** Theratechnologies announced positive 26-week results for its confirmatory Phase 3 clinical trial, evaluating the efficacy of tesamorelin, in patients with HIV-associated lipodystrophy. As described in the protocol and agreed to by the Food and Drug Administration (FDA) through the Special Protocol Assessment process, the study was powered to detect an 8% reduction in visceral adipose tissue (VAT) versus placebo. While meeting its primary endpoint as well as important secondary endpoints, the study confirms the positive results obtained in the initial Phase 3 study and provides crucial data to prepare the New Drug Application (NDA) dossier.

Update on the strategic review

On June 20, 2008, within the context of the market activity and the positive clinical results disclosed two days prior, Theratechnologies confirmed, by issuing a press release, that its strategic review process was still ongoing, that it is entertaining discussions with a number of companies and that the Committee of Independent Directors in charge of the process regularly reports to the Board of Directors. Although no decision has yet been made, and as was stated on January 29, 2008, the Company will advise its shareholders of any material development in due course.

Agreement signed with the Massachusetts General Hospital and Dr. Grinspoon

In mid-May, Theratechnologies announced the conclusion of an agreement with both the Massachusetts General Hospital ("MGH") and Dr. Steven Grinspoon to explore the use of

tesamorelin in relative growth hormone deficient abdominally obese subjects. Under the terms of the agreement, the MGH, under the direction of Dr. Grinspoon, will sponsor and conduct a clinical trial with tesamorelin in subjects that have excess VAT with a moderate growth hormone deficiency and who are abdominally obese. Theratechnologies is providing tesamorelin for this study and has no other obligations, financial or otherwise, in the execution of this study while retaining the benefits from the results generated in this trial.

License agreement signed with PDC Biotech GmbH

Finally, Theratechnologies announced, last May 12, the signing of an exclusive license agreement with PDC Biotech GmbH (PDC), a privately-held company based in Austria. This agreement involves Theratechnologies' family of antagonists of the prostaglandin F2α receptor for use in preterm labour and primary dysmenorrhea (painful menstruation). Due to a refocusing of its business in late 2005, Theratechnologies had granted, in June 2006, an option to license THG113.31 which had shown efficacy *in vitro* and in animal models in preterm labour. With this exclusive license, PDC will be developing both an injectable formulation for the treatment of preterm labour and a topical formulation of this compound for the treatment of primary dysmenorrhea. The terms of the agreement were not disclosed.

MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE SECOND QUARTER

Revenues

Consolidated revenues for the three-month period ended May 31, 2008, amounted to $716,000 compared to $805,000 in 2007. For the six-month period ended May 31, 2008, consolidated revenues were $1,315,000 compared to $1,092,000 for the same period in 2007. Revenues are mainly composed of interest on investments. Interest revenues decreased from the second quarter 2008 compared to those of 2007 due to less liquidities over the period and a decrease in market interest rates. For the six-month period ended May 31, 2008, interest revenues were higher than those of 2007 reflecting the higher level of liquidities reported in the first quarter of 2008.

R&D Activities

Research and Development (R&D) expenditures, before tax credits, totalled $9,927,000 for the second quarter of 2008, compared to $6,576,000 in 2007. For the six-month period ended May 31, 2008, R&D expenditures were $19,411,000, compared to $14,676,000 for the same period in 2007. The increase in R&D spending in 2008 is primarily related to an increase in costs associated with various projects in completing the tesamorelin clinical program in HIV associated lipodystrophy. R&D expenses, in 2008, also increased due to spending related to the preparation of the New Drug Application for the Food and Drug Administration in the United States. Finally, for the six-month period ended May 31, 2008, the stock-based compensation expenses attributable to R&D amounted to $317,000 compared to $927,000 in 2007. The exceptionally high stock-based compensation expenses in 2007 were due to a special distribution of stock options to all employees.

Other Expenses

For the second quarter of 2008, general and administrative expenses, patents and amortization of other assets (G&A) amounted to $1,939,000, compared to $2,084,000 for the same period in 2007. For the six-month period ended May 31, 2008, the G&A amounted to $3,976,000 compared to $4,077,000 for the same period in 2007. In 2008, the G&A expenses were comparable to those in 2007 and include the expenses associated with the growth and the development of the Company as well as fees related to the strategic review which is being led by the Board of Directors. In 2007, the Company had reported an exchange rate loss of $408,000. The stock-based compensation expenses attributable to SG&A amounted to $120,000 compared to $860,000 in 2007. The exceptionally high stock-based compensation expenses in 2007 were due to a special distribution of stock options to all employees.

Selling and market development costs amounted to $949,000 for the second quarter 2008, compared to $466,000 for the same period in 2007. For the six-month period ended May 31, 2008, selling and market development expenses amounted to $1,906,000, compared to $861,000 for the same period in 2007. The increase in these expenses is related to the pre-commercialization efforts for the tesamorelin program in HIV-associated lipodystrophy, which include the activities associated with the continuing medical education program.

Net Results

Reflecting the advancement of the clinical program, the Company recorded a second-quarter net loss of $11,398,000 ($0.20 per share), compared to $8,089,000 ($0.15 per share) for the same period in 2007. For the six-month period ended May 31, 2008, the loss was

$22,289,000 ($0.39 per share), compared to losses of $17,528,000 ($0.35 per share) in 2007.

Quarterly Financial Information
The selected financial information provided below is derived from the Company's unaudited quarterly financial statements for each of the last eight quarters.

	2008				2007			2006
	Q2	Q1	Q4	Q3	Q2	Q1	Q4	Q3
Revenues	**$ 716**	$ 599	$ 1,294	$ 748	$ 805	$ 287	$ 367	$ 412
Net Loss	**$ (11,398)**	$ (10,891)	$ (10,279)	$ (9,781)	$ (8,089)	$ (9,439)	$ (6,942)	$ (7,251)
Basic and diluted loss per share	**$ (0.20)**	$ (0.20)	$ (0.19)	$ (0.18)	$ (0.15)	$ (0.20)	$ (0.15)	$ (0.16)

Financial Position
Theratechnologies maintains an adequate financial position. As at May 31, 2008, liquidities, which include cash and bonds, amounted to $69,832,000, and tax credits receivable amounted to $2,608,000 for a total of $72,440,000.

During the first quarter 2008, the Company completed a public offering for the sale and issuance of 3,500,000 common shares for a cash consideration of $29,750,000. Issue costs totalled $1,938,000 resulting in net proceeds of $27,812,000. During the first half of 2008, the Company issued 91,337 common shares following the exercise of stock options, for cash proceeds of $286,000. During the second quarter of 2008, the Company received subscriptions for an amount of $28,000 for the issue of 3,671 common shares to its employees in connection with its share purchase plan.

For the three-month period ended May 31, 2008, the burn rate from operating activities, excluding changes in operating assets and liabilities, was $10,853,000, compared to $7,467,000 in 2007. For the six-month period ending May 31, 2008, the burn rate from operating activities, excluding changes in operating assets and liabilities, increased to $21,250,000, compared to $15,029,000 for the same period in 2007. The increased burn rate in 2008 reflects the planned increase of activities regarding the Phase 3 program which includes the activities associated with the pre-commercialization of tesamorelin, including the continuing medical education program.

New Accounting Policies
Refer to note 2 of the Company’s unaudited Consolidated Financial Statements for the second quarter 2008.

The adoption of the new accounting policies described above has no impact on the financial results of the Company.

Outstanding Share Data
Between June 1 and July 8, 2008, 15,334 options were exercised, at an average exercise price of $3.69 per share, for cash proceeds of $57,000. On July 8, 2008, the number of shares issued and outstanding was 58,141,470, while outstanding options granted under the stock option plan were 2,193,967.

Contractual obligations
Apart from the financings mentioned above, there were no material changes in contractual

obligations during the first half, other than in the ordinary course of business.

Economic and Industry Factors
Economic and industry factors were substantially unchanged from those reported in the Company's 2007 annual report.

About Theratechnologies
Theratechnologies (TSX:TH) is a Canadian biopharmaceutical company that discovers innovative drug candidates in order to develop them and bring them to market. The Company targets unmet medical needs in financially attractive specialty markets. Its most advanced program is tesamorelin, now in a confirmatory Phase 3 clinical trial for a serious metabolic disorder known as HIV-associated lipodystrophy. The Company also has other projects at earlier stages of development.

Additional information about Theratechnologies
Further information about Theratechnologies is available on the Company's website at www.theratech.com. Additional information is also available on SEDAR at www.sedar.com.

Forward-Looking Information
This press release and the management's discussion and analysis for the second quarter contained herein contain certain statements that are considered "forward-looking information" within the meaning of applicable securities legislation. This forward-looking information includes, but is not limited to, information regarding the Phase 3 clinical program of tesamorelin, the filing of a New Drug Application ("NDA") with the U.S. Food and Drug Administration (the "FDA") and the commercialization of tesamorelin in HIV-associated lipodystrophy. Words such as "will", "may", "could", "should", "outlook", "believe", "plan", "envisage", "anticipate", "expect" and "estimate", or the negatives of these terms or variations of them and the use of the future or conditional tense as well as similar expressions denote forward-looking information.

Forward-looking information is based upon a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company's control, that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These risks and uncertainties include, but are not limited to the risk that the Company may not obtain all required approvals from the FDA to market its products, the risk that the Company's products may not be accepted by the market, the risk that unexpected events delay or prevent the advancement of the tesamorelin clinical program, challenges, regulatory or other, which could impact the NDA submission and delays or excessive costs that could result from the use of third party suppliers.

Although the forward-looking information contained herein is based upon what the Company believes are reasonable assumptions, investors are cautioned against placing undue reliance on this information since actual results may vary from the forward-looking information. Certain assumptions used in these forward looking statements, and the Company's anticipated objectives, take into consideration that the administration of tesamorelin to patients will not have any significant adverse side-effects, that the Company will have access to all the data and necessary resources to submit the NDA, that the estimated costs for the tesamorelin clinical program will not vary, or if they vary, the variation will be insignificant and that the Company will continue to have a good business relationship with its third party suppliers.

Consequently, all of the forward-looking information contained herein is qualified by the foregoing cautionary statements, and there can be no guarantee that the results or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequences or effects on the Company, its business, its financial condition or its results of operation. Investors are referred to the Company's public filings available at www.sedar.com. In particular, further details and descriptions of these and other factors are disclosed in the "Risk and Uncertainties" section of the Company's Annual Information Form, dated January 29, 2008, for the year ended November 30, 2007. The Company does not undertake to update or amend such forward-looking information whether as a result of new information, future events or otherwise, except as may be required by applicable law.

Information:

Andrea Gilpin
Vice President, IR & Communications
Phone: 514-336-7800, ext. 205
agilpin@theratech.com

Luc Tanguay
Senior Executive Vice President and
Chief Financial Officer
Phone: 514-336-7800, ext. 204
ltanguay@theratech.com